The presence of eNOS was detected using an anti-eNOS antibody (Transduction, Lexington KY) followed by a donkey anti-rabbit secondary antibody conjugated to horseradish peroxidase. Peroxidase activity was determined using an ECL Western blotting kit (Amersham) LCMP-00312-2003.R2 5 and by exposure of membranes to X-ray film. The relative amount of eNOS protein was quantitated by laser densitometry and analyzed using a Hewlett Packard Scanjet IIcx. Image analysis was performed with SigmaScan/Image Software (Jandel Scientific). Protein loading in each lane of the gel was monitored by probing the membranes with an anti-β actin antibody (Sigma, St. Louis MO). The eNOS protein level in control cells was arbitrarily set at 100%, and the levels in treated cells are shown relative to control cells. f). Preparation of BPAEC membrane and cytosolic fractions. BPAECs were treated with 1 µΜ Ang II for the desired time. The cells were then homogenized in a Dounce homogenizer using 1.5 ml Buffer A (20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 100 µM phenylmethylsulfonylflouride, 1 µM leupeptin, 1 µM pepstatin, 0.1 µM aprotonin containing 0.33 M sucrose). The homogenate was then centrifuged at 1000 X g for 10 min, 4 o C. The postnuclear fraction (after 1000 x g) was then subjected to ultracentrifugation at 100,000 x g for 1 hr at 4 o C. The supernatant, which contains cytosolic protein, was collected. The pellet was solubilized in Buffer A with 1% Triton X-100, incubated on ice for 1 hr, and then centrifuged at 100,000 x g for 30 min at 4 o C. The resulting supernatant contained solubilized membrane proteins.
g). Analysis of eNOS mRNA levels. Isolation of total RNA, and analyses of eNOS mRNA and 18S rRNA levels were performed as described previously (32). The eNOS mRNA level in control cells was arbitrarily set at 100%, and the levels in treated cells are shown relative to control cells.
h). Assay of NOS activity by quantitation of nitrite production. Confluent BPAECs in 6-well plates were cultured in DMEM containing 2% fetal bovine serum, without phenol red and For the hypoxic studies, the pulmonary arterial rings were either left untreated or treated with 1 µM Ang II. At the desired times (2, 4, 6, 8 hr following Ang II stimulation), hypoxic challenge was measured by the following procedure. The vessels were precontracted with 3x10 -8 M U-46619, a stable thromboxane A 2 analog, which provides a stronger, more reproducible, hypoxic contraction in these arteries. After reaching steady state tone (2.5 g), the gas was changed from air/5%CO 2 to 95%N 2 /5%CO 2 , hypoxic contractions were recorded for 10 min and the tissues then reoxygenated with air/5%CO 2 . For examining the effects of receptor antagonists, the rings were treated with either 10 µM candesartan or 10 µM PD123319 for 15 min prior to the addition of buffer or 1 µM Ang II. After 6 hours, hypoxic vasoconstriction was measured. The 6-hour time point was chosen based on the time-frame in which Ang II had stimulated a significant increase in eNOS protein expression in BPAEC (32). Hypoxic challenge was performed in the presence of 10 µM indomethacin to rule out the contribution of vasodilator prostaglandins. In order to examine the role of the endothelium in modulating Ang II dependent hypoxic vasoconstriction, the endothelium was removed by gentle rubbing of the lumen of the vessel and confirmation was determined by the loss of a relaxant response to acetylcholine (10 -8 to10 -6 M). To determine the effect of eNOS inhibition on hypoxic vasoconstriction, vessels were treated with 100 µM L-NAME 20 min prior to the hypoxic challenge. Data are reported as the increase in force caused by hypoxia (in the presence and absence of Ang II) above the 2.5 g U- (Fig. 1A) followed by dot-blot analysis with the radiolabelled PCR products (Fig 1B) . The expected sizes for the PCR products are 201 base pairs for AT 1 receptor, 197 base pairs for the AT 2 receptor, and 274 base pairs for GAPDH. Dot blot hybridization analysis (Fig. 1B) with the radiolabeled PCR products demonstrated that BPAECs express both the AT 1 and AT 2 receptor messages, while BPASMCs express only the AT 1 receptor mRNA.
To demonstrate that BPAECs translate the receptor mRNAs into proteins, expression of the AT 1 (50 kDa) and AT 2 (50 kDa) receptor proteins was investigated by Western blot analysis ( Fig. 2A) . BPAECs express the AT 1 receptor, the AT 2 receptor and β-actin (42 kDa), whereas BPASMCs express only the AT 1 receptor protein and α-smooth muscle actin (42 kDa). In the presence of the AT 2 receptor competing peptide, the 50 kDa molecular weight band recognized by the anti-AT 2 receptor antibody was completely blocked, whereas, the competing peptide had LCMP-00312-2003.R2 9 no effect on the 50 kDa molecular weight band recognized by the anti-AT 1 receptor antibody.
To determine the percentage of BPAECs that express both the AT 1 3). Effects of Ang1-7 and Ang3-8 on eNOS protein expression. Since published studies (6, 9, 33, 35) suggest that it may be another peptide product of the RAS such as Ang1-7 or Ang3-8 that is responsible for the vasodilatory effect of Ang II, we examined whether these Ang II fragments could stimulate NO production in BPAECs. Treating BPAECs with either Ang1-7 or Ang3-8 (1 µM) for 2-8 hours did not stimulate a significant increase in eNOS protein expression (data not shown). 4). Ang II dependent increase in NO production is mediated via the AT 2 receptor. To determine which receptor subtype mediates the Ang II dependent increase in NO production in BPAECs, the effects of AT 1 and AT 2 receptor antagonists on eNOS mRNA, protein and nitrite LCMP-00312-2003.R2 11 production were determined. BPAECs were pretreated for 15 min with either 10 µM losartan (an AT 1 antagonist), 10 µM PD123319 (an AT 2 antagonist) or both followed by stimulation with 1 µΜ Ang II for 6 hours (32). Losartan alone (2.5± 0.4 fold vs control; n= 5, P < 0.05) as well as in the presence of Ang II (3.2 ± 0.95 fold vs. control; n = 5, P < 0.01), stimulated an increase in eNOS mRNA expression (Fig. 4A) . In contrast, PD123319 alone had no effect on eNOS mRNA levels; however, it did prevent the Ang II (1 µΜ) dependent increase in eNOS mRNA levels (1.5 ± 0.35 vs. 2.6 ± 0.32-fold increase, respectively, Fig. 4A ). The losartan induction of eNOS mRNA expression, alone and in the presence of Ang II, was prevented when the cells were also pretreated with PD123319 ( Fig 4A) . Fig. 4C ). When BPAECs were treated with losartan alone there was a significant increase in NO production (84.4 +/-17.7 nmoles/mg protein; n = 6, P < 0.05) that was further enhanced in the presence of Ang II (128.5 +/-25.5 nmoles/mg protein; n = 6, P < 0.01).
Pretreatment of BPAECs with PD123319 blocked the Ang II-dependent nitrite accumulation (22.7 +/-11.6 nmoles/mg protein) as well as prevented the losartan-induction (alone and in the presence of Ang II) of nitrite accumulation at 8 hours (Fig 4C) .
Because the losartan enhancement of eNOS protein expression was prevented by PD123319, we wanted to determine if the losartan-dependent increase in eNOS protein expression involves endogenous synthesis of Ang II that, in turn, may selectively stimulate the AT 2 receptor. Preincubation of BPAECs with an anti-Ang II antibody (10 µg/ml; Santa Cruz Biotechnology) for 5 min prevented both the Ang II-and losartan-dependent increase in eNOS protein expression at 8 hours (Fig 5) . Control IgG had no effect on eNOS protein expression.
L-NAME, an analog of arginine that inhibits NO production, decreased basal production of NO and also prevented the Ang II dependent increase in nitrite accumulation at 8 hours (97.3 +/-10 vs 0.5 +/-0.43nmoles/mg protein; n = 6, P < 0.01). Previously published studies (42, 45) demonstrated that the AT 2 receptor is linked to acute activation of NOS, so we first investigated whether the AT 2 receptor plays a role in mediating Ang II-dependent acute vasoconstriction in isolated pulmonary arteries. To achieve this goal, pulmonary arteries were treated with losartan, candesartan or PD123319 for 15 min. Ang II was then added to the vessels and contraction was measured immediately. Losartan inhibited approximately 55% of the Ang II-dependent acute vasoconstriction (3.92 ± 0.4 g vs. 8.6 ± 0.74 g; n = 8, P< 0.05), whereas candesartan completely blocked the response (Fig. 7) . In contrast, PD123319 had no effect on Ang II induced vasoconstriction (7.2 ± 1.8 g vs. 8.6 ± 0.74 g; n = 8).
These data confirm that acute Ang II-dependent vasoconstriction is mediated via the AT 1 receptor and that signaling via the AT 2 receptor does not modulate acute responses to Ang II in pulmonary arteries.
Since Ang II causes a sustained enhancement of pulmonary hypoxic vasoconstriction (42), we then chose to examine the role of the AT 2 receptor in regulating this Ang II response.
To confirm that the effects of Ang II were due to the peptide and/or receptor antagonist and not due to a change in vessel reactivity overtime, hypoxic vasoconstriction in control and Ang II-LCMP-00312-2003.R2 14 treated vessels for 2 to 8 hr was examined. In arterial rings treated with the cyclooxygenase inhibitor, indomethacin alone (control vessels), HPV remained relatively stable over an 8 hr period ranging from 2.76 ± 0.46 g at 2 hr to 2.00 ± 0.66 g at 8 hr (Fig 8A) . Furthermore, in the Ang II treated vessels, hypoxic vasoconstriction began to increase at 2 hr (4.23 ± 0.42 g) and remained significantly enhanced up to 8 hours (3.78 ± 1.17 g; n = 12, P< 0.05 at each time point).
We then examined the roles of the AT 1 and AT 2 receptors in modulating hypoxic vasoconstriction at 6 hours, a time at which there is a significant Ang II-dependent increase in eNOS protein expression (see Fig 3B) . To perform this study, the vessels were pretreated with either candesartan or PD123319 for 15 min prior to stimulation with Ang II. After 6 hours hypoxic vasoconstriction was determined. The AT 1 receptor antagonist, candesartan, completely blocked the Ang II-dependent increase in hypoxic vasoconstriction (4.85 ± 1.32 g vs. 2.64 ± 0.76 g; n=12, P< 0.05; Fig. 8B ). Candesartan was used in this part of the study because it completely inhibited acute Ang II-dependent contraction, whereas losartan only inhibited 55% of the response (see Fig 7) . In contrast, treatment of the vessels with the AT 2 receptor antagonist, PD123319, augmented hypoxic vasoconstriction in the Ang II treated rings (6.93 ± 2.94 g), as compared to those treated with Ang II alone (4.85 ± 1.32 g; n=12, P< 0.05; Fig. 8B ). If vessels were pretreated with both candesartan and PD123319, Ang II did not enhance hypoxic contractions (data not shown). When the endothelium was removed from the pulmonary arteries, PD123319 no longer enhanced hypoxic vasoconstriction (Fig 8B; -ENDO Treatment of the pulmonary vessels with 100 µM L-NAME for 20 min prior to hypoxic challenge stimulated an approximately two to three-fold increase in pulmonary contraction as compared to control vessels (5.77 ± 1.5 vs. 2.42 ± 0.38 g; n=6). However, when the vessels had been pretreated with 100 µΜ L-NAME, there was no difference in the hypoxic vasoconstriction between the control and Ang II-treated vessels.
Since Ang1-7 and Ang3-8 have been shown previously to elicit vasodilatory responses in the lungs (6, 33, 35) , we examined the effects of these metabolites on both acute vessel responses and on the Ang II-enhanced HPV. Neither Ang3-8 nor Ang1-7 induced a vasodilatory response in pulmonary arterial vessels (Fig. 7) . In addition, Ang3-8 did not effect the hypoxic contraction of the vessels at 6 hours, either alone (2.42 ± 0.38 g; n=6) or in the presence of Ang II (4.12 ± 0.83g; n=6). Furthermore, Nor 1 ,Leu 3 , Ang IV, an AT 4 receptor antagonist, did not affect the Ang II-dependent acute vasoconstriction nor did it affect the Ang II-dependent enhanced hypoxic vasoconstriction at 6 hours (data not shown).
Discussion:
In the present study, we provide experimental evidence that the AT 2 receptor is linked to an increase in NO production in pulmonary endothelial cells and that signaling via the (14) can be higher than the concentrations measured in the plasma.
Although there are published studies (38, 40) demonstrating that Ang II increases NO production in multiple cell types, there is disagreement as to the receptor subtype linked to this increase in NO. Moreover, Ang II has been shown to stimulate NO production both by increasing eNOS gene expression (32, 38) and by activating eNOS enzyme activity (40) . Data obtained with the specific AT 1 , AT 2 and AT 4 receptor antagonists as well as the studies examining the sensitivity to DTT, demonstrated that Ang II stimulates an increase in eNOS mRNA, which in turn leads to an increase in eNOS protein and NO production in BPAECs, via the AT 2 receptor. In agreement with our studies, Ritter and colleagues (38) found that Ang II increases eNOS protein expression via an AT 2 receptor, calcineurin-NF-AT pathway in cardiomyocytes. On the other hand, Siragy and Carey (43) found that activation of the AT 2 receptor leads to acute production of NO via a bradykinin-dependent pathway. leads to an increase in cytosolic calcium. Previously published studies (7, 16, 29, 34, 38) suggest that components of this AT 1 receptor-linked pathway may regulate NO production; however the data are not consistent. While Ohara and colleagues (34) A number of reports (6, 9, 33, 35) have shown that angiotensin fragments such as Ang1-7
and Ang3-8 may mediate some of the effects of Ang II in the cardiovascular system. Previous studies have shown that these peptides elicit a vasodilatory response in the lung (6, 33, 35) ; however, our studies do not support a role for these metabolites in modulating pulmonary vascular tone. Neither Ang1-7 nor Ang3-8 stimulated an increase in eNOS protein expression in BPAEC nor did they elicit a vasodilatory response in pulmonary arterial vessels. This discrepancy may be due to different species and cell types, different experimental conditions and Ang II concentrations, as well as different lengths of time of exposure to Ang II.
Several studies suggest that Ang II may be an important modulator of hypoxia-dependent pulmonary hypertension (10, 31, 39, 42) , nevertheless, very little is known about the Ang II receptors and the mechanism by which they regulate pulmonary vasoconstriction and vessel remodeling. Recently, Chassagne and colleagues (10) demonstrated that chronic hypoxia induces a transient increase in AT 1 and AT 2 receptors in the rat lung. While they were able to demonstrate that the vasoconstrictive response to Ang II was due mainly to activation of the AT 1 receptor, they were unable to identify a role for the AT 2 receptor in their hypoxic model. Our The endothelium produces many vasoactive compounds known to regulate pulmonary vascular tone (1); however, the role of the endothelium in hypoxic vasoconstriction remains controversial. Even though Ang II enhanced hypoxic vasoconstriction in bovine pulmonary arteries when the endothelium was removed; it did not reach statistical significance.
Nonetheless, endothelial denudation did prevent the PD123319 enhancement of Ang II-induced hypoxic contractions in these vessels, suggesting that Ang II stimulates the production of both endothelial-derived contracting and relaxing factors that can ultimately affect pulmonary vascular tone. Additionally, the cell experiments support the isolated pulmonary vessel studies suggesting that the AT 2 receptor dependent-linked vasodilator may be endothelial derived NO, as pulmonary vascular smooth muscle cells do not express the AT 2 receptor.
The concentration of L-NAME (100 µM) which significantly inhibited NO production in BPAECs, augmented hypoxic contractions as compared to untreated pulmonary arterial vessels.
In support of our results, other investigators have shown that decreased production of NO and/or LCMP-00312-2003.R2 20 decreased bioavailability to NO enhances acute hypoxic vasoconstriction in pulmonary arteries (4, 13, 44) . Furthermore, Fagan and colleagues (17) demonstrated that NO is an important modulator of the pulmonary vasculature response to mild hypoxia in homozygous and heterozygous eNOS-null mice. However, in contrast to our results studies have shown that blocking eNOS activity had no effect (22, 26) or even suppressed (46) hypoxic vasoconstriction.
In this study when the pulmonary arteries were treated with L-NAME there was no significant difference in the hypoxic vasoconstriction between control and Ang II-treated vessels. One possible explanation is that removal of an endogenous vasodilator resulted in maximal contraction under hypoxic conditions and that the vessels were not able to further constrict in response to Ang II. We propose that blocking NO synthesis by L-NAME or blocking the AT 2 receptor dependent increase in NO potentiates hypoxic vasoconstriction, suggesting the NO opposes vasoconstriction in the presence of increased tone.
The results of the present study, taken together with our previous findings (32), demonstrate that Ang II stimulates an increase in eNOS mRNA and protein expression as well as an increase in NO production via an AT 2 receptor, and that signaling via the AT 1 receptor appears to negatively regulate NO production in the pulmonary endothelium. Furthermore, we have demonstrated that the Ang II-enhancement of hypoxic contractions in pulmonary arteries is mediated via the AT 1 receptor, whereas signaling via an endothelial-AT 2 receptor serves to limit the severity of the contractions. We propose that this AT 2 receptor-dependent increase in eNOS may provide a protective mechanism in the pulmonary circulation when challenged by elevated levels of Ang II, such as that seen during hypoxic conditions and in renin-dependent systemic 
